Milestone Fee. Genzyme shall pay Alnylam Fifty Million Dollars ($50,000,000) upon the dosing of the first patient in the first Phase III Study for a Global AT3 Licensed Product.
Appears in 2 contracts
Sources: Aln At3 Global License Terms (Alnylam Pharmaceuticals, Inc.), Global License Agreement (Alnylam Pharmaceuticals, Inc.)